Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pennsylvania Department of Health | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment outcomes.
The primary aim is to determine whether comprehensive medication management with review of PGx testing results improves depression symptoms, compared with usual care.
Participants 18 years of age or older who have undergone PGx testing (e.g. through an independent biobanking study (Pitt+Me Discovery) who require initiation or adjustment of antidepressant therapy will be randomly assigned to receive either PGx-guided comprehensive medication management or usual care. Those who receive usual care will receive their PGx results at the end of the study. Researchers will compare the groups to assess whether PGx-guided care provided in partnership with community pharmacists and prescribers results in better depression and medication outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Comprehensive medication management with PGx testing results | Experimental | Participants will have a study visit with a community pharmacist for comprehensive medication management with review of PGx testing results. |
|
| Usual care | Other | Participants will receive no study intervention (usual care) and will have a comprehensive medication management with review of PGx testing results at the end of the study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Comprehensive medication management with PGx testing results | Other | A comprehensive medication management with PGx testing includes a pharmacist-provided review of health history, past/current medications, and assessment of potential medication related problems. A review of PGx testing results will be integrated to identify any PGx-related medication issues. Recommendations will then be made to study participants' providers (regular care team) for any decisions regarding potential therapy changes. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Patient Health Questionnaire (PHQ-8) score | The Patient Health Questionnaire-8 (PHQ-8) is an 8-item self-report measure assessing depressive symptoms. Each item is scored from 0-3, producing a total score of 0-24, with higher scores indicating more severe depressive symptoms. Standard severity categories are minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-24). | Baseline, 6 Weeks, 12 Weeks, 6 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in the Extent of Adherence and Reasons for Nonadherence Survey (Voils et al.) score | The Extent of Adherence and Reasons for Nonadherence Survey (Voils et al.) is a validated self-report measure assessing medication adherence over the past 7 days. It is scored on a 1-5 Likert scale and averaged to produce a continuous score, with higher scores indicating better adherence. The Reasons for Nonadherence scale assesses specific barriers to taking medication as prescribed, with items rated on a 1-5 scale and assessed individually to identify the degree to which each barrier contributed to missed doses. |
| Measure | Description | Time Frame |
|---|---|---|
| Community pharmacists' needs for expert support in deploying PGx | Community pharmacists' needs for expert support in deploying PGx Number and types of questions asked by community pharmacists to PGx experts on study team through the duration of the study. | 6 Months |
INCLUSION CRITERIA:
At targeted community pharmacy for:
Depressive symptoms confirmed by PHQ8 assessment (>5 indicating at least mild depressive symptoms)
UPMC patient (or able/willing to become one) and has UPMC provider (or able/willing to obtain one)
Signed consent to join Pitt+Me Discovery biobanking research study.
English-speaking
EXCLUSION CRITERIA:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Linda Prebehalla, RN | Contact | (412) 624-8129 | CompassPGx@pitt.edu | |
| Philip E Empey, PharmD, PhD | Contact | (412) 624-7219 | compasspgx@pitt.edu |
| Name | Affiliation | Role |
|---|---|---|
| Philip E Empey, PharmD, PhD | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15260 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Usual Care | Other | Participants will receive no study intervention (usual care) and will have a comprehensive medication management with review of PGx testing results at the end of the study. |
|
| Baseline, 6 Months |
| Change in Generalized Anxiety Disorder Assessment (GAD-7) score | The Generalized Anxiety Disorder Assessment (GAD-7) is a 7-item self-report measure assessing anxiety symptoms over the past two weeks, with items scored 0-3 for a total score of 0-21; higher scores indicate more severe anxiety, categorized as minimal (0-4), mild (5-9), moderate (10-14), and severe (15-21). | Baseline, 6 Weeks, 12 Weeks, 6 Months |
| Proportion of pharmacist recommendations were accepted | Proportion of pharmacist recommendations to address medication-related problems that were accepted by providers as assessed by EHR and fill data review. | 6 months |
| Change in frequency of CPIC/FDA guideline concordant prescribing | Change in frequency of concordance of participant medication regimen with pharmacogenomics prescribing recommendations according to the Clinical Pharmacogenomics Implementation Consortium (CPIC) and U.S. Food & Drug Administration (FDA) guidelines using electronic health record data. | Baseline, 6 Months |
| Number of adverse events as assessed using the Frequency, Intensity, and Burden of Side Effect rating scale (FIBSER). | The Frequency, Intensity, and Burden of Side Effect Rating Scale (FIBSER) is a 3-item self-report measure assessing medication side effects. It evaluates the frequency, intensity, and functional burden of side effects over the past week, with each item rated on a 0-6 scale; higher scores indicate more frequent, severe, or burdensome side effects. Clinically, a total score of 0-2 typically requires no change in treatment, 3-4 side effects may warrant targeted management, and 5-6 indicates that treatment modification should be considered to improve tolerability and adherence. | Baseline, 6 Weeks, 12 Weeks, 6 Months |
| Frequency of Actionable Genotypes | Frequency of actionable genotypes (in the entire study population) based on report of a genotype-predicted phenotype. Actionable genotypes are defined as those with recommendations for a change in prescribing by a CPIC (Clinical Pharmacogenetics Implementation Consortium) guidelines or FDA recommendations. | 6 months |
| Number of participant medications with PGx guidance based on PGx testing results. | This measure counts the number of a participant's medications for which pharmacogenomic (PGx) guidance is available based on PGx testing results. Medications with PGx guidance may have dosing recommendations, alternative drug options, or monitoring considerations informed by the participant's genetic profile. | 6 months |
| Change in healthcare utilization | Change in participant ER visits, hospitalizations, urgent care visits, specialist appointments, primary care appointments, and unplanned care using UPMC EHR data. | From Baseline to 6 Months |